

Home

- 2. Patient Advice
- 3. Gold sodium thiomalate

Gold Sodium Thiomalate

Medically reviewed by Drugs.com. Last updated on Aug 26, 2024.

Uses Dosage Directions Interactions Side effects Warnings

Pronunciation

(gold SOW dee um thye oh MAL ate)

Index Terms

Sodium Aurothiomalate

Pharmacologic Category

Gold Compound

Pharmacology

Unknown, may decrease prostaglandin synthesis or may alter cellular mechanisms by inhibiting sulfhydryl systems

Excretion

Urine (60% to 90%); feces (10% to 40%)

Onset of Action

Delayed; may require up to 6 months

Half-Life Elimination

6 to 25 days; may be prolonged with multiple doses

Use: Labeled Indications

Rheumatoid arthritis: Adjunctive treatment of active rheumatoid arthritis.

Juvenile rheumatoid arthritis: Adjunctive treatment of juvenile rheumatoid arthritis.

Contraindications

Hypersensitivity to gold compounds or any component of the formulation; systemic lupus erythematosus; blood dyscrasias or a history of agranulocytosis, hemorrhagic diathesis or drug-induced granulocytopenia or anemia; renal disease; hepatic impairment; history of severe adverse effects with previous gold therapy (eg, bone marrow aplasia or other hematological disorders, exfoliative dermatitis, necrotizing enterocolitis, pulmonary fibrosis); significant dermatitis, including urticaria or eczema; pregnancy; breastfeeding.

Dosing: Adult

Rheumatoid arthritis: IM: 10 mg first week; 25 mg second week; then 25 to 50 mg/week for an additional 20 weeks or until development of toxicity. For patients with modest improvement, a prolonged period of weekly injections may be maintained. For patients with a good to excellent response, continue 50 mg tapered progressively to every 2 to 4 weeks based on tolerability and response.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Pediatric

Rheumatoid arthritis: IM: Initial: Test dose of 10 mg is recommended, followed by 1 mg/kg/week (maximum: 50 mg/injection); maintenance: 1 mg/kg/dose (maximum: 50 mg/injection) at every-other-week intervals for 2 to 20 weeks, then every 3 to 4 weeks. Early improvement may be observed after 6 to 8 weeks of therapy; months of therapy may be required before clinical improvement is observed.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Adjustment for Toxicity

Detailed Gold sodium thiomalate dosage information

Mild to moderate reactions: Temporarily interrupt therapy; may be cautiously resumed 2 or 3 weeks after reaction has subsided. If therapy resumed, administer a test dose of 5 to 10 mg; if the test dose is tolerated, therapy may be cautiously continued in larger doses on subsequent injections at a decreased frequency.

Severe reactions: Permanently discontinue therapy.

Administration

IM: Deep IM injection into the upper outer quadrant of the gluteal region. Observe patient for 30 minutes after

administration for anaphylactic reaction.

Storage

Store at 15°C to 30°C (59°F to 86°F). Protect from light. Should not be used if solution is darker than pale yellow.

Drug Interactions

Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated. *Monitor therapy*

Aspirin: May enhance the adverse/toxic effect of Gold Sodium Thiomalate. Specifically, liver function tests may be elevated when these agents are combined. *Monitor therapy*

PenicillAMINE: Gold Sodium Thiomalate may enhance the adverse/toxic effect of PenicillAMINE. Specifically, this combination may increase the risk for serious hematologic and/or renal adverse reactions. *Avoid combination*

Phenylbutazone: May enhance the adverse/toxic effect of Gold Sodium Thiomalate. Specifically, the risk for hematologic adverse effects may be increased. *Monitor therapy*

Gold sodium thiomalate drug interactions (more detail)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%:

Dermatologic: Skin rash (30%)

Gastrointestinal: Mucous membrane lesion (20%)

Genitourinary: Proteinuria (10% to 15%)

1% to 10%: Hematologic & oncologic: Thrombocytopenia (1% to 3%), leukopenia (2%)

Frequency not defined:

Cardiovascular: Bradycardia, syncope, vasomotor symptoms (nitritoid reaction)

Central nervous system: Encephalitis, encephalopathy, Guillain-Barre syndrome, metallic taste, peripheral neuropathy

Dermatologic: Alopecia, blue-gray skin pigmentation (chrysiasis, irreversible), bullous dermatitis, erythema of skin, exfoliative dermatitis, pruritus

exicilative derinatitis, prantas

Endocrine & metabolic: Albuminuria

Gastrointestinal: Diarrhea, enterocolitis, stomatitis

Genitourinary: Nephrotic syndrome

Hematologic & oncologic: Agranulocytosis, aplastic anemia, eosinophilia, neutropenia, pancytopenia

Hepatic: Cholestatic jaundice, hepatotoxicity

Hypersensitivity: Anaphylaxis, angioedema, nonimmune anaphylaxis, tongue edema

Neuromuscular & skeletal: Arthralgia

Ophthalmic: Corneal deposits (gold)

Renal: Acute renal failure

Respiratory: Interstitial pulmonary disease, pulmonary fibrosis, pulmonary infiltrates

Gold sodium thiomalate side effects (more detail)

Related/similar drugs

Rinvoq

Rinvoq (upadacitinib) is used to treat rheumatoid arthritis, psoriatic arthritis, atopic ...

Reviews & ratings

7.0 / 10

223 Reviews

View more

Humira

Humira is a tumor necrosis factor blocker that is used to treat many inflammatory conditions such ...

Reviews & ratings

6.4 / 10

698 Reviews

View more

FEATURED

Xeljanz

Xeljanz (tofacitinib) is an oral Janus kinase (JAK) inhibitor that may be used alone or with other ...

Reviews & ratings

5.7 / 10

145 Reviews

View more

Plaquenil

Plaquenil is used to treat or prevent malaria and to treat the symptoms of rheumatoid arthritis ...

Reviews & ratings

6.4 / 10

158 Reviews

View more

Enbrel

Enbrel is used to treat rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Learn about ...

Reviews & ratings

7.7 / 10

306 Reviews

View more

Remicade

Remicade is used to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn's ...

Reviews & ratings

7.0 / 10

213 Reviews

View more

Rituxan

Rituxan IV infusion is a cancer medicine that interferes with the growth and spread of cancer cells ...

Reviews & ratings

8.2 / 10

50 Reviews

View more

Orencia is a type of biologic that is given by intravenous infusion or subcutaneous injection which ...

Reviews & ratings

6.0 / 10

71 Reviews

View more

Rituximab

Rituximab is a monoclonal antibody drug used to treat non-hodgkin lymphoma, chronic lymphocytic ...

Reviews & ratings

7.6 / 10

166 Reviews

View more

Adalimumab

Adalimumab is used to treat plaque psoriasis, Crohn's disease, ulcerative colitis, rheumatoid ...

Reviews & ratings

6.4 / 10

737 Reviews

View more

Warnings/Precautions

Concerns related to adverse effects:

- Dermatologic reactions: Dermatitis and lesions of the mucous membranes are common and may be serious; pruritus may precede the early development of a skin reaction. Consider alternative therapy in patients with dermatitis; may increase risk and/or symptoms of gold toxicity may be more difficult to detect. Use is contraindicated in patients with significant dermatitis, including urticaria or eczema.
- GI effects: Signs of toxicity include persistent diarrhea, stomatitis, and enterocolitis; avoid use in patients with prior inflammatory bowel disease.
- Hematologic effects: Signs of toxicity include hematologic depression (depressed hemoglobin, eosinophilia, leukocytes, granulocytes, or platelets). Use is contraindicated in patients with a history of blood dyscrasias or a history of agranulocytosis, hemorrhagic diathesis, or drug-induced granulocytopenia or anemia. Symptoms of gold toxicity may be

difficult to detect in patients with prior abnormalities; consider alternative therapy.

- Hepatic effects: May be associated with the development of cholestatic jaundice. Use is contraindicated in patients with hepatic impairment.
- Hypersensitivity reactions: Rare hypersensitivity reactions, including anaphylactic shock, syncope, bradycardia, thickening of the tongue, difficulty in swallowing and breathing, and angioedema have been reported in association with injections of sodium aurothiomalate; treatment should be discontinued if these reactions occur. In addition, a vasomotor (nitritoid) reaction characterized by acute flushing and tachycardia may occur within minutes of injection; this reaction should be differentiated from anaphylaxis and therapy may be continued, but a careful evaluation of risk versus benefit should be undertaken and extreme caution should be exercised before resuming therapy, particularly in patients with cardiovascular disease.
- Pulmonary toxicity: May be associated with interstitial fibrosis; monitor closely.
- Renal effects: Renal toxicity ranges from mild proteinuria to nephrotic syndrome. Use is contraindicated in patients with renal disease.

Disease-related concerns:

Cardiovascular disease: Use caution in patients with heart failure, hypertension, or cerebrovascular disease.

Other warnings/precautions:

- · Administration: Must not be injected IV.
- Experienced physician: Physicians should be experienced with chrysotherapy and should be familiar with the toxicity and benefits of therapy.
- · Monitoring: Frequent monitoring of patients for signs and symptoms of toxicity will prevent serious adverse reactions.

Monitoring Parameters

CBC with differential, platelet count, hemoglobin determination, and urinalysis for protein, white cells, red cells, and casts, at baseline and prior to each injection. Skin and oral mucosa should be inspected for skin rash, bruising, or oral ulceration/stomatitis. Specific questioning for symptoms such as pruritus, rash, stomatitis or metallic taste should be included.

Reproductive Considerations

Females of childbearing potential should be instructed to avoid pregnancy.

Pregnancy Considerations

Gold crosses the placenta and accumulates in the fetus.

Use is contraindicated during pregnancy.

More about gold sodium thiomalate

- Check interactions
- · Compare alternatives
- Reviews (3)
- · Side effects
- Dosage information
- During pregnancy
- Drug class: antirheumatics
- Breastfeeding

Related treatment guides

Rheumatoid Arthritis


Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

DRUG STATUS

Availability



Pregnancy & Lactation



Risk data available

CSA Schedule*

N/A Not a controlled drug

User Reviews & Ratings

3 Reviews

Drugs.com Mobile App

Access drug & treatment information, identify pills, check interactions and set up personal medication records.





About Drugs.com Advertising policy Attribution & citations

Terms & privacy

Terms of use

Editorial policy

Privacy policy

Support

Help center

Sitemap

Contact us











Subscribe to our newsletter for the latest medication news, new drug approvals and FDA alerts.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex (updated 7 Apr 2025), Cerner Multum™ (updated 13 Apr 2025), ASHP (updated 10 Apr 2025) and others.







Copyright © 2000-2025 Drugs.com. All rights reserved.

×